Applied Molecular Transport Inc (AMTI)
Applied Molecular Transport is a clinical-stage biopharmaceutical company utilizing its proprietary technology platform to design and develop a pipeline of oral biologic product candidates. Co.'s proprietary technology platform allows Co. to utilize existing natural cellular trafficking pathways to facilitate the transport of diverse therapeutic payloads across the epithelial barriers. Co. has two oral biologics in clinical development. Co.'s product candidate, AMT-101, is in Phase 2 development for patients with rheumatoid arthritis. Co.'s second product candidate, AMT-126 is in Phase 1 development for diseases related to intestinal epithelium barrier function defects.
|
April 25, 2024 3:35 PM Eastern
Hold (1.67 out of 4)
100th percentile
|
|